401
Participants
Start Date
December 8, 2017
Primary Completion Date
August 20, 2021
Study Completion Date
January 6, 2022
SP-102
injection
Placebo
injection
Semnur Research Site 20, Winston-Salem
Semnur Research Site 11, Durham
Semnur Research Site 48, Charleston
Semnur Research Site 77, Greenville
Semnur Research Site 28, Marietta
Semnur Research Site 64, Marietta
Semnur Research Site 10, Newnan
Semnur Research Site 56, Fernandina Beach
Semnur Research Site 81, Jacksonville
Semnur Research Site 53, Winter Park
Semnur Research Site 13, Tampa
Semnur Research Site 61, Tampa
Semnur Research Site 49, St. Petersburg
Semnur Research Site 75, Mobile
Semnur Research Site 46, Cleveland
Semnur Research Site 43, Cuyahoga Falls
Semnur Research Site 42, Greenfield
Semnur Research Site 63, Chicago
Semnur Research Site 12, Chicago
Semnur Research Site 19, Chicago
Semnur Research Site 40, Bloomington
Semnur Reseach Site 62, Overland Park
Semnur Research Site 65, Omaha
Semnur Research Site 36, Oklahoma City
Semnur Research Site 54, Plano
Semnur Research Site 35, Tyler
Semnur Research Site 15, Houston
Semnur Research Site 38, Boise
Semnur Research Site 59, Draper
Semnur Research Site 52, Phoenix
Semnur Research Site 58, Tempe
Semnur Research Site 60, Las Vegas
Semnur Research Site 18, La Jolla
Semnur Research Site 47, Laguna Woods
Semnur Research Site 70, Los Gatos
Semnur Research Site 51, Burlington
Semnur Research Site 30, Shrewsbury
Collaborators (1)
Worldwide Clinical Trials
OTHER
Semnur Pharmaceuticals, Inc.
INDUSTRY
Scilex Pharmaceuticals, Inc.
INDUSTRY